GH Research PLC (NASDAQ:GHRS) Receives $32.00 Average PT from Brokerages

Shares of GH Research PLC (NASDAQ:GHRS - Get Free Report) have been given an average rating of "Buy" by the seven brokerages that are presently covering the firm, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $32.00.

Several equities research analysts recently issued reports on GHRS shares. Royal Bank of Canada began coverage on GH Research in a research note on Friday, March 7th. They issued an "outperform" rating and a $31.00 price target for the company. Stifel Nicolaus lifted their price objective on GH Research from $18.00 to $32.00 and gave the company a "buy" rating in a report on Thursday, February 27th. Wall Street Zen downgraded GH Research from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. HC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of GH Research in a research report on Friday, May 9th. Finally, Guggenheim dropped their price target on GH Research from $32.00 to $29.00 and set a "buy" rating for the company in a research note on Friday, May 9th.

Institutional Investors Weigh In On GH Research

A number of institutional investors have recently made changes to their positions in GHRS. Two Sigma Investments LP bought a new position in shares of GH Research during the fourth quarter worth about $117,000. Millennium Management LLC acquired a new stake in GH Research during the 4th quarter valued at approximately $145,000. BNP Paribas Financial Markets bought a new position in GH Research during the 4th quarter worth approximately $44,000. Northern Trust Corp lifted its position in shares of GH Research by 26.8% in the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company's stock worth $286,000 after purchasing an additional 8,641 shares during the period. Finally, Woodline Partners LP lifted its position in shares of GH Research by 112.0% in the 4th quarter. Woodline Partners LP now owns 78,949 shares of the company's stock worth $553,000 after purchasing an additional 41,711 shares during the period. Institutional investors own 56.90% of the company's stock.

GH Research Stock Down 0.3%

Shares of GHRS traded down $0.04 during midday trading on Friday, reaching $12.72. 229,125 shares of the stock were exchanged, compared to its average volume of 188,795. The stock's 50 day simple moving average is $10.73 and its 200 day simple moving average is $10.39. The company has a market cap of $661.80 million, a P/E ratio of -16.10 and a beta of 0.97. GH Research has a twelve month low of $6.00 and a twelve month high of $20.50.

GH Research (NASDAQ:GHRS - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.42. As a group, analysts predict that GH Research will post -0.8 earnings per share for the current year.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).